Provided By PR Newswire
Last update: Oct 18, 2025
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read more at prnewswire.comNASDAQ:ACAD (10/27/2025, 9:45:05 AM)
22.25
+0.23 (+1.04%)
Find more stocks in the Stock Screener


